Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News HTG Molecular Diagnostics Inc HTGMQ

Healthcare Medical Devices
HTG Molecular Diagnostics, Inc. is a life science company. The Company is focused on advancing precision medicine and drug discovery through its transcriptome-wide profiling and advanced drug discovery platform technologies. The Company is engaged in the sales of its HTG EdgeSeq system and integrated next-generation sequencing-based (NGS-based) HTG EdgeSeq research use only (RUO) assays and... see more

Recent & Breaking News (GREY:HTGMQ)

HTG to Highlight the Advantages of its Drug Discovery Engine at the 2023 BIO International Convention

GlobeNewswire May 18, 2023

HTG Highlights the Advantages of Its Drug Discovery Engine

GlobeNewswire May 16, 2023

HTG Molecular Diagnostics Reports First Quarter 2023 Results and Provides Recent Business Highlights

GlobeNewswire May 10, 2023

HTG Provides Update on Drug Discovery Partnering Initiative

GlobeNewswire April 25, 2023

HTG Announces Key First Quarter Milestone Achievements for Drug Discovery

GlobeNewswire April 18, 2023

HTG Technology Featured in Numerous Scientific Posters at the AACR Annual Meeting April 16-19

GlobeNewswire April 6, 2023

HTG Provides a Year-End Update on its Drug Discovery Business and Attends LifeSci Partners 2023 Corporate Access Event

GlobeNewswire January 9, 2023

HTG Announces Certain Preliminary 2022 Unaudited Financial Results

GlobeNewswire January 6, 2023

HTG Molecular Diagnostics Provides Highlights of its Second Event in Drug Discovery KOL Webcast Series

GlobeNewswire December 28, 2022

HTG Molecular Diagnostics Announces Closing of a $10 Million Public Offering

GlobeNewswire December 23, 2022

HTG Molecular Diagnostics Announces Pricing of a $10 Million Public Offering

GlobeNewswire December 21, 2022

HTG Announces One-for-Twelve Reverse Stock Split

GlobeNewswire December 20, 2022

HTG Molecular Diagnostics Announces the Next Event in its RNA Profiling in Drug Discovery KOL Webcast Series

GlobeNewswire December 9, 2022

HTG Technology Featured Across Numerous Abstracts at Upcoming Scientific Conferences

GlobeNewswire December 6, 2022

HTG Molecular Diagnostics Reports Third Quarter 2022 Results

GlobeNewswire November 10, 2022

HTG to Collaborate With OmiCure, Providing Transcriptomic Data Across Several Cancer Indications

GlobeNewswire October 26, 2022

HTG Provides Update on Third Quarter Progress Toward Its Transcriptome-Informed Approach to Drug Discovery

GlobeNewswire October 12, 2022

HTG Molecular Diagnostics to Participate in the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference

GlobeNewswire September 26, 2022

The Fundación Instituto Valenciano de Oncología Leverages HTG Technology for Breast Cancer Laboratory-Developed Test

GlobeNewswire September 20, 2022

HTG Molecular Diagnostics Reports Second Quarter 2022 Results

GlobeNewswire August 11, 2022